MakitaN, IiriT. 2013. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid, 23:151–159.
2.
MotzerRJ, HutsonTE, TomczakP, MichaelsonMD, BukowskiRM, RixeO, OudardS, NegrierS, SzczylikC, KimST, ChenI, BycottPW, BaumCM, FiglinRA. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356:115–124.
3.
FerraraN, GerberHP, LeCouterJ. 2003. The biology of VEGF and its receptors. Nat Med, 9:669–676.
4.
FerraraN, HillanKJ, GerberHP, NovotnyW. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3:391–400.
5.
KambaT, TamBY, HashizumeH, HaskellA, SenninoB, MancusoMR, NorbergSM, O'BrienSM, DavisRB, GowenLC, AndersonKD, ThurstonG, JohoS, SpringerML, KuoCJ, McDonaldDM. 2006. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 290:H560–H576.
6.
Van der VeldtAA, HendrikseNH, HarmsH, ComansEF, PostmusPE, SmitEF, LammertsmaAA, LubberinkM. 2010. Quantitative parametric perfusion images using oxygen-15 labeled water and a clinical PET-CT scanner: test-retest variability in lung cancer. J Nucl Med, 51:1684–1690.
7.
Van der VeldtAA, LubberinkM, BahceI, WalravenM, de BoerMP, GreuterHN, HendrikseNH, ErikssonJ, WindhorstAD, PostmusPE, VerheulHM, SernéEH, LammertsmaAA, SmitEF. 2012. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell, 21:82–91.
8.
Van CruijsenH, Van der VeldtA, HoekmanK. 2009. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci, 14:2248–2268.
9.
Van der VeldtAA, De BoerMP, BovenE, EringaEC, Van den EertweghAJ, Van HinsberghVW, SmuldersYM, SernéEH. 2010. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer Drugs, 21:439–446.
10.
CarmelietP, MoonsL, LuttunA, VincentiV, CompernolleV, De MolM, WuY, BonoF, DevyL, BeckH, ScholzD, AckerT, DiPalmaT, DewerchinM, NoelA, StalmansI, BarraA, BlacherS, VandenDriesscheT, PontenA, ErikssonU, PlateKH, FoidartJM, SchaperW, Charnock-JonesDS, HicklinDJ, HerbertJM, CollenD, PersicoMG. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med, 7:575–583.
